ATX-MS-1467
- Overview
- How does it work?
- How is it given?
- What are the results so far?
- Side effects
- What further studies are planned?
- References
Overview
| Drug in development |  |
|---|---|
| ATX-MS-1467 |  |
| Other names | |
| What is it for? | Relapsing remitting multiple sclerosis (MS) |
- ATX-MS-1467 is an experimental drug treatment for relapsing remitting multiple sclerosis. It is injected under the skin once every two weeks.
- ATX-MS-1467 is intended to selectively inhibit the immune system's harmful attack on the nerve coating by reducing T-cell response to myelin
- Preliminary study in 6 people with secondary progressive MS showed a reduction in the T-cell response to myelin basic protein.
- No side effects reported to date.
How does it work?
Some of the damage to nerves in MS may be caused by T-cells (a type of white blood cell or lymphocyte) which mistakenly identify the myelin coating of nerves as 'foreign'. Myelin basic protein (MBP) is believed to be an important component in the myelination of nerves in the brain and spinal cord. ATX-MS-1467 consists of four short peptides (chains of amino acids, the building blocks of proteins) derived from MBP. ATX-MS-1467 is intended to selectively inhibit the immune system's harmful attack on the nerve coating by reducing T-cell response to myelin.
How is it given?
ATX-MS-1467 is injected under the skin (either intra-dermally or subcutaneously) once every two weeks.
What are the results so far?
In a phase I/IIa study, 6 people with secondary progressive MS received increasing doses 7 to 14 days apart. The results showed a reduction in the T-cell response to myelin basic protein and the treatment was found to be safe and well tolerated in this small group of people. The study was not designed to provide data on clinical efficacy.
Side effects
No side effects have been reported from the phase I clinical trial.
What further studies are planned?
-
Phase I study
A phase I study is currently underway to evaluate ATX-MS-1467 in 40 people with relapsing remitting MS and is recruiting in the UK. Study centres include Stoke on Trent, Sheffield, Nottingham, Oxford, London and Plymouth.
Estimated completion date September 2012
Further details of this study.